176750.KQ DuChemBIO Co.,Ltd.

Healthcare Drug Manufacturers - Specialty & Generic KOSDAQ
6,090 KRW
Close of Oct 30, 2026
5,100 12,770
Market cap
KRW 173B
P/E
26.6x
P/B
3.35x
ROE
8.1%
Dividend yield
-
Fundamental score
0.7/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 176750.KQ undervalued?

Graham number
Price6,090
Graham value3,059
Premium99.1%

176750.KQ trades 99.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

DuChemBIO Co.,Ltd. fundamental analysis

4 of 22 checks passed

ROE 0/2

Low return on equity (8.1%), below 10%.

ROA 0/1

Return on assets (5.4%) is below the industry median (5.4%).

Profit Consistency 1/2

Profitable for 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-18.9%) is below the industry median (88.7%).

Revenue Growth 1/2

Revenue grew 6.0% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 0/1

EBIT is 4.7x against interest expense, below 5x.

PE vs Market 0/1

PE (26.6x) is above the market median (11.3x).

PE vs Industry 0/1

PE (26.6x) is above the industry median (19.0x).

PBV 0/1

Price to book (3.4x) is above the industry median (1.5x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 89.2, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

DuChemBIO Co.,Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About DuChemBIO Co.,Ltd.

DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of b…

Full company profile